argenx Acquires Forte for $2.2 Billion

Company argenx, Forte Biosciences Event Type M&A / Acquisition Agreement Modality Monoclonal antibody (anti-CD122) Asset FB102 Target CD122 (shared IL-2/IL-15 receptor beta chain) Disease Area Celiac disease, vitiligo, alopecia areata (autoimmune) Summary argenx agreed to acquire Forte Biosciences for $77 per share in cash, representing…